CISD1

CDGSH iron-sulfur domain-containing protein 1 · Q9NZ45 · CISD1 on Sugi Atlas →

29,167 patent compounds predicted against CISD1, 21,293 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Furosemide (SCHEMBL230219)	0.76	11/20
Azosemide (SCHEMBL230300)	0.47	10/20
Furosemide (SCHEMBL231204)	0.92	9/20
Furosemide (SCHEMBL232152)	0.92	9/20
Furosemide (SCHEMBL230594)	0.88	9/20
Furosemide (SCHEMBL231246)	0.88	9/20
SCHEMBL230662	0.68	9/20
SCHEMBL230706	0.68	9/20
Furosemide (SCHEMBL231673)	0.64	9/20
Furosemide (SCHEMBL9811)	1.00	8/20
Furosemide (SCHEMBL428921)	1.00	8/20
Furosemide (SCHEMBL231742)	0.80	8/20
Furosemide (SCHEMBL187248)	0.76	8/20
SCHEMBL573193	0.62	8/20
SCHEMBL231936	0.58	8/20
Furosemide (SCHEMBL229185)	0.86	7/20
Furosemide (SCHEMBL229240)	0.86	7/20
Furosemide (SCHEMBL232189)	0.83	7/20
Furosemide (SCHEMBL232438)	0.83	7/20
Furosemide (SCHEMBL231485)	0.79	7/20

Clinical trials — most relevant to CISD1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Bovine Lactoferrin to Prevent and Cure Iron Deficiency and Iron Deficiency Anemia in Complicated Pregnancies	PHASE4	COMPLETED
Effect of Pioglitazone Administered to Patients With Friedreich's Ataxia: Proof of Concept	PHASE3	COMPLETED
Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy	PHASE2	ACTIVE_NOT_RECRUITING
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers	PHASE2	NOT_YET_RECRUITING
Study of the Effects of Iron on Lung Blood Pressure at High Altitude	PHASE2	WITHDRAWN
Broccoli Sprout Extracts Trial to See if NRF2 is Enhanced by Sulforaphane Treatment in Patients With COPD	PHASE2	COMPLETED
Tolerability of Enteral NAC in Infants	PHASE1	NOT_YET_RECRUITING
The Effects of a Glutathione Precursor (FT061452),on Serum and Intracellular Glutathione Levels	PHASE1	COMPLETED
Investigations Into ISCU Myopathy or Iron Sulfur Scaffold U Protein Myopathy	nan	COMPLETED
Dietary Effects of Sulfur Amino Acids	nan	COMPLETED
Natural History Study of FDXR Mutation-related Mitochondriopathy	nan	COMPLETED
Tecfidera Diffusion Tensor Imaging	nan	COMPLETED
Biocollection in MyeloDysplastic Syndrome (P-MDS)	nan	RECRUITING
Hemochromatosis and Iron Overload Screening Study (HEIRS)	nan	COMPLETED
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia	nan	NOT_YET_RECRUITING
Effect of Sulfur Amino Acid Depletion and Acetaminophen on Plasma Glutatione	nan	COMPLETED
Assessing the Polygenic Burden of Rare Disruptive Mutations in Parkinson's Disease	nan	UNKNOWN
Thiol/Disulphide Homeostasis in Unexplained Infertility	nan	COMPLETED
Genetic Determinants of Congenital Heart Disease Outcomes	nan	COMPLETED
LIPCAR, Cuproptosis, and Α-SMA in the Pathogenesis of AMI and Remodeling	nan	NOT_YET_RECRUITING
Cerebellar Mutism Syndrome Study	nan	RECRUITING
Expression of Fas Protein in Skin Biopsies of Participants With Scarring Alopecia	nan	COMPLETED
GDF 15 in Sickle Cell Disease and Hereditary Spherocytosis	nan	UNKNOWN
Role of USP35 in the Detection of Ferroptosis in Juvenile Autoimmune Hepatitis	nan	NOT_YET_RECRUITING
Molecular Epidemiology of Parkinson's Disease	nan	COMPLETED
Medtronic Genetic Arrhythmia Markers for Early Detection (GAME Study)	nan	COMPLETED
PCD New Gene Discovery	nan	COMPLETED
Effects of Preoperative Oral Carbohydrate Loading on Maternal Thiol-disulfide Homeostasis	nan	COMPLETED
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA	nan	RECRUITING
Mitochondrial Function of Immune Cells in Sepsis	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CISD1 binder may also engage these)

Protein	Name	Similarity
B0K020	—	1.000	B0K020 →
Q91WS0	—	1.000	Q91WS0 →
Q3ZBU2	—	1.000	Q3ZBU2 →
B4K5X8	—	0.994	B4K5X8 →
B3RML8	—	0.993	B3RML8 →
B4MBU8	—	0.991	B4MBU8 →
Q29BX8	—	0.991	Q29BX8 →
B4GPI0	—	0.990	B4GPI0 →
B4HZ81	—	0.989	B4HZ81 →
B4JYJ2	—	0.988	B4JYJ2 →
B4QZI8	—	0.988	B4QZI8 →
B4PQ50	—	0.988	B4PQ50 →
B3P5J1	—	0.987	B3P5J1 →
C4A0P0	—	0.987	C4A0P0 →
C3ZWH9	—	0.986	C3ZWH9 →
B4NFN4	—	0.986	B4NFN4 →
B3M1H7	—	0.985	B3M1H7 →
Q9VAM6	—	0.985	Q9VAM6 →
Q05B71	—	0.982	Q05B71 →
CISD2	CDGSH iron-sulfur domain-containing protein 2	0.982	landscape →
Q9CQB5	—	0.981	Q9CQB5 →
A8X858	—	0.981	A8X858 →
Q6PCF8	—	0.979	Q6PCF8 →
Q8IQ70	—	0.979	Q8IQ70 →
Q5I027	—	0.977	Q5I027 →
B3N8S9	—	0.977	B3N8S9 →
Q7SH49	—	0.976	Q7SH49 →
B4LRY2	—	0.976	B4LRY2 →
Q6AZG1	—	0.976	Q6AZG1 →
Q9W0S3	—	0.976	Q9W0S3 →